Current evidence supports the use of HPV testing on self-samples for overcoming barriers to screening and reaching under-screened women.1
can potentially extend screening coverage by increasing participation rates and represents a unique opportunity for expansion to hard-to-reach populations.1,2
More women screened means less cases of cervical cancer.1,3
As such, HPV testing on self-collected samples has become an integral part of the strategy to eliminate cervical cancer as a public health problem in Europe.3
"All European nations should, by 2030, reach at least 90% HPV vaccine coverage [...], achieve 70% of screening coverage […], providing also HPV testing on self-samples for non- or under-screened women; and manage 90% of screen-positive women." The European response to the WHO call to eliminate cervical cancer as a public health problem, 2021.3
Self-collected and clinician-collected samples provide a similar performance for the detection of precancerous lesions when used with PCR-based HPV tests.2
A meta-analysis of 56 test accuracy studies and 25 randomised trials concluded that PCR-based hrHPV assays were as sensitive and specific on self-collected samples as on clinician-collected samples.2
BD offers a solution specifically designed for self-collection that provides a convenient logistical chain from sample to testing and has the lowest proportion of invalid results compared to other PCR-based HPV assays.11-13
BD solutions for self-collection
LEARN MORE